

COMPARISON OF FERRIC SULFATE AND GLUTERALDEHYDE AS A PULPOTOMY AGENT

L.G.VIJAYAALAKSHMI*

INTRODUCTION :

A major goal in pediatric dentistry is to maintain the primary dentition in an intact state until the permanent successors erupt. Pulpotomies help maintain arch integrity by allowing preservation of teeth that would otherwise be destined for extraction. Pulp therapy for the vital primary tooth has evolved over the past 20 years with the introduction of new pulp therapy medicaments and the return of old techniques. The main objective of pulp therapy in the primary dentition is to retain every primary tooth as a fully functional component in the dental arch to allow for proper mastication, phonation, swallowing, preservation of the space required for eruption of permanent teeth and prevention of detrimental psychological effects due to tooth loss^{1,2}. To fulfill this major goal, vital pulp therapy through pulpotomy, which refers to surgical removal of the entire coronal inflamed pulp leaving the vital radicular pulp intact within the canals, is the most widely accepted technique for treating primary teeth with irreversible inflammation affecting the pulp chamber.

The pulpotomy is still the most widely used treatment for the primary tooth where caries has closely approximated the pulp so that complete removal would expose the pulp³. The most commonly used pulpotomy pulp medicaments are formocresol, ferric sulfate, and mineral trioxide aggregate (MTA)⁴. However, an old technique, indirect pulp therapy (IPT), also known as indirect pulp capping, has made a return as a viable alternative to pulpotomy in the same teeth indicated for a pulpotomy⁵. The formocresol pulpotomy technique is considered the most universally taught and preferred pulp therapy for primary teeth at the present time and since it was introduced in 1904 by Buckley it has undergone a lengthy evolution to

* FINAL YEAR BDS, GUIDE NAME: DR. DEEPA, DEPARTMENT OF PEDODONTICS, SAVEETHA DENTAL COLLEGE & HOSPITALS, CHENNAI-77.

hemorrhage might minimize the chances for inflammation and internal resorption believed by some investigators (Schroeder) to be associated with physiologic clot formation. Investigators have not explained how clotting itself could curtail these activities²³.

Ranly proposes the possibility that the metalprotein clot at the surface of the pulp stumps may act as a barrier to the irritative components of the sub-base and in that capacity, functions solely in a passive manner²⁴. Currently, an exact mechanism explaining why ferric sulfate would be expected to be superior to previous pulpotomy agents, such as formocresol, has yet to be provided. In fact, the technique is quite similar to performing ZOE pulpotomies. The human studies with ferric sulfate are limited in time and have small sample sizes. Additional long-term studies with increased sample sizes should be conducted before ferric sulfate can be recommended as a substitute for the “gold standard” formocresol technique. Several studies compared the clinical success of ferric sulfate with formocresol.

A retrospective study by Nikki L. Smith et al based on patients receiving ferric sulfate pulpotomies with a sub-base of zinc oxide eugenol in a clinical practice over a five year period revealed the success rates was found lower than those reported previously in the literature for ferric sulfate pulpotomies, but are comparable with those reported for 1:5 dilution, 5-minute formocresol pulpotomies²⁵. A study by PAPAGIANNOULIS on clinical studies on FS as a pulpotomy medicament in primary teeth suggested that ferric sulphate be used, rather than formocresol, for pulpotomies of primary teeth as the latter has been blamed for systemic and local side effects on the developing successors²⁶.

A clinical study of ferric sulfate as a pulpotomy agent in primary teeth by Ay-Luen Fei, BDS, MSc Richard D. Udin, DDS were performed on 83 primary molars in 62 patients. Ferric sulfate/formocresol was placed on the pulpal stumps, and teeth were followed for 3, 6, 12 month periods. After the one year follow-up, 28 of 29 teeth treated with ferric sulfate (FS group) were considered successful and 21 of teeth treated with formocresol (FC group) were judged to be successful. The FS group demonstrated greater combined clinical and radiographic success than the FC group at the one-year recall ($P < 0.05$). The combined overall success rate of the FS group was 96.6% and the FC group was 77.8%.²⁷

GLUTERALDEHDYE AS A PULPOTOMYAGENT :

Glutaraldehyde for pulp fixation was proposed by s-Gravenmade in 1975. Glutaraldehyde is a colourless solution that has a mild odour and a boiling point of 183°C to 187°C, is soluble in water and produces a mild acidity on contamination. This di-aldehyde has a limited shelf life and a cross-linking ability superior to that of formocresol. In recent years, glutaraldehyde has been proposed as an alternative to formocresol based on its superior fixative properties, self-limiting penetration, low antigenicity, low toxicity and elimination of cresol^{28,29}. Glutaraldehyde produces rapid surface fixation. Narrow zone of eosinophilic stained and compressed fixed tissue is found beneath the area of application which blends with underlying normal pulp^{29,30}.

Hill reported minimal antimicrobial concentration of glutaraldehyde as 3.125%³¹. Ranly, Garcia Godoy in 1987 noted that increasing the concentration and longer time improves fixation and suggested the use of 4% Glutaraldehyde for 4 minutes or 8% Glutaraldehyde for 2 minutes³⁰. Sandra Maria et al. suggested the use of 2% for 5 minutes^{32,33}. Presently, 2% glutaraldehyde for 5 minutes is used for pulpotomy. Various studies report improved success rates. Garcia-Godoy reported that despite of high success rates the drawbacks in using glutaraldehyde includes the cost and inadequate fixation that leaves a deficient barrier susceptible for sub base irritation resulting in internal resorption³⁴.

Researchers Vivek Kumar Adlakhia, Preetika Chandna et al found the success rate was found to be 100% clinically and 80.33% radiographically in the hydroxyapatite crystals group and 100% clinically and radiographically in the glutaraldehyde group³⁵ because glutaraldehyde appears to produce tissue fixation without causing tissue necrosis at high concentrations. Although it depresses PMN adherence at intermediate concentrations, it does not seem to stimulate PMN adherence and cause inflammatory tissue damage at low concentrations.

[Shashidhar Chandrashekar](#), [Jyothi Shashidhar](#) compared the clinical and radiological effects of formocresol and glutaraldehyde pulpotomies in various exposed vital human primary molars.³⁶ The 2% glutaraldehyde compound was promising when compared to ferric sulfate and formocresol in an *in vivo* study. The only limitations of glutaraldehyde are instability due to short shelf-life and it has to be freshly prepared. In this study, the clinical and radiographic success of formocresol, glutaraldehyde and ferric sulfate were compared as a pulpotomy

medicament in primary molars at 3-month intervals over 1 year. Internal resorption was found in all the medicaments. Clinical success was higher than the radiological success³⁷. Long-term (36 months) success rates of four different glutaraldehyde preparations (2%-buffered and unbuffered, 5%-buffered and unbuffered) as a pulpotomy agent in pulp exposed primary molars were evaluated. The 5% buffered solution group showed highest success rate, whereas 5% unbuffered solution showed the lowest³⁸.

CONCLUSION:

Success of pulpotomy depends on various vital factors like case selection, clinical diagnosis, intraoperative diagnosis and most importantly the material used for the pulpotomy procedures so called “Ideal Pulpotomy material” is not yet been identified. Formocresol Pulpotomy enjoys very good clinical and radiographic success rates, and is still a popular pulpotomy material despite the concerns raised due to its toxicity, mutagenicity and carcinogenicity. Clinical studies report good success rates of Ferric sulfate 15.5% and glutaraldehyde as alternatives to FC. One of the major limitations of using MTA is its high cost and its use in pediatric dentistry practice can become almost prohibitive in some circumstances. Hence, FS can still be considered a valid and inexpensive solution for pulpotomies in primary teeth.

REFERENCE:

1. Dummett CO Jr, Kopel HM. Pediatric endodontics. In: Ingle JI, Bakland LK, editors. Endodontics. 5th ed. Hamilton: BC Decker Inc.; 2002. p.861-902.
2. Ounsi HF, Debaybo D, Salameh Z, Chebaro A, Bassam H. Endodontic considerations in pediatric dentistry: A clinical perspective. *Int Dent South Afr* 2009;11:40-50.
3. Fuks A, Kupietzki A, Guelmann M. Pulp therapy for the primary dentition. In: *Pediatric Dentistry : Infancy through Adolescence*. St. Louis, Mo.: Elsevier/Saunders; 2013;333-351.
4. Fuks AB. Vital pulp therapy with new materials for primary teeth: New directions and treatment perspectives. *Pediatr Dent*. 2008; 30:211-219.
5. American Academy of Pediatric Dentistry. 2014a Guideline on pulp therapy for primary and immature permanent teeth. *Pediatr Dent*. 2014;36:242-250.

6. Primosch RE, Glomb TA, Jerrell RG: Primary tooth pulp therapy as taught in predoctoral pediatric dental programs in the United States. *Pediatric Dentistry* 19:118-122, 1997.
7. Buckley JP: The chemistry of pulp decomposition, with a rational treatment for this condition and its sequelae. *Am Dent J* 3:764, 1904.
8. Berger JE: Pulp tissue reaction to formocresol and zinc oxide-eugenol. *J Dent Child* 32:13-28, 1965.
9. Beaver HA, Kopel HM, Sabes WR: The effect of zinc oxide-eugenol cement on a formocresolized pulp. *J Dent Child* 33:381-396, 1966.
10. Redig DF: Comparison and evaluation of two formocresol pulpotomy techniques utilizing "Buckley's" formocresol. *J Dent Child* 35:22-30, 1968.
11. Morawa AP, Straffon LH, Han SS, Corpron RE: Clinical evaluation of pulpotomies using dilute formocresol. *J Dent Child* 42:360-363, 1975.
12. Rolling I, Thylstrup A: A 3-year clinical follow-up study of pulpotomized primary molars treated with the formocresol technique. *Scand J Dent Res* 83:47-53, 1975.
13. Willard RM: Radiographic changes following formocresol pulpotomy in primary molars. *ASDC J Dent Child* 43:414-415, 1976.
14. Magnusson BO: Therapeutic pulpotomies in primary molars with the formocresol technique. *Acta Odontol Scand* 36:157-165, 1977.
15. Fuks AB, Bimstein E: Clinical evaluation of diluted formocresol pulpotomies in primary teeth of school children. *Pediatric Dentistry* 3:321-324, 1981.
16. Verco PJW, Allen KR: Formocresol pulpotomies in primary teeth. *J Int Ass Dent Child* 15:51-55, 1984.
17. Lewis B: Formaldehyde in dentistry: a review for the millennium. *J Clinical Ped Dent* 22:167-177, 1998.
18. Swenberg JA, Kerns WD, Mitchell RI: Induction of squamous cell carcinomas of the rat nasal cavity by inhalation exposure to formaldehyde vapor. *Cancer Research* 40:3398-3402, 1980.
19. Pashley EL, Myers DR, Pashley DH: Systemic distribution of ¹⁴C-formaldehyde from formocresol-treated pulpotomy sites. *J Dent Res* 59:602-607, 1980.
20. Myers DR, Shoaf HK, Dirksen TR: Distribution of ¹⁴C-formaldehyde after pulpotomy with formocresol. *JADA* 96:805-812, 1978.
21. Fischer DE: Tissue management: A new solution to an old problem. *General Dentistry* 178-182, May-June 1987.
22. Lemon RR, Steele PJ, Jeanson BG: Ferric sulfate hemostasis: effect on osseous wound healing. 1. left in situ for maximum exposure. *J Endodontics* 19:170-173, 1993.
23. Schroeder U: Effect of an extra-pulpal blood clot on healing following experimental pulpotomy and capping with calcium hydroxide. *Odont Revy* 24:257-268, 1973.

24. Ranly DM: Pulpotomy therapy in primary teeth: new modalities for old rationales. *Pediatric Dentistry* 16:403-409,1994.
25. Nikki L. Smith, DDS, MS N. Sue Seale, DDS, MSD Martha E. Nunn, DDS, PhD .**Ferric sulfate pulpotomy in primary molars.A retrospective study** .*Pediatric Dentistry* – 22:3, 2000 .
- 26.L. PAPAGIANNOULIS .**Clinical studies on ferric sulphate as a pulpotomy medicament in primary teeth** .EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY • 3/2002 .
- 27.Seow WK, Thong YH. Modulation of polymorphonuclear leukocyte adherence by pulpotomy medicaments: Effects of formocresol, glutaraldehyde, eugenol, and calcium hydroxide. *Pediatr Dent* 1986;8:16-21.
- 28.Doyle WA, McDonald RE, Mitchell DF. Formocresol versus calcium hydroxide in pulpotomy. *ASDC Journal of Dentistry for Children*. 1962; 29: 86-97.
- 29.Ranly DM, Garcia-Godoy F, Horn D. Time, concentration and pH parameters for the use of glutaraldehyde as a pulpotomy agent: an in vitro study. *Pediatric Dentistry*. 1987; 9: 199-203.
30. Kopel HM, Bernick, Zachrisson E, DeRomero SA. The effects of glutaraldehyde on primary pulp tissue following coronal amputation: an in vivo histologic study. *Journal of Dentistry*. 1980; 47: 425-430.
- 31.Hill SD. Comparison of antimicrobial and cytotoxic effects of glutaraldehyde and formocresol. *Oral Surgery*. 1991; 71: 89.
- 32.Fuks AB, Eidelman E, Cleaton-Jones P, Michaeli Y. Pulp response to ferric sulfate, diluted formocresol and IRM in pulpotomized primary baboon teeth. *ASDC Journal of Dentistry for Children*. 1997; 64: 254-259.
- 33.Maria S, Gama P. Comparative study between formocresol and glutaraldehyde in pulpotomy- Literature review. *Revista Dental Odontalgia*. 2005; 2: 27-32.
34. Garcia-Godoy F. A 42 month clinical evaluation of glutaraldehyde pulpotomies in primary teeth. *Journal of Indian Society of Pedodontics*. 1986; 10: 148-155.
- 35.Vivek Kumar Adlakha, PreetikaChandna,andNamita Singh.A Comparative Evaluation of Hydroxyapatite Crystals and Glutaraldehyde as Agents for Pulpotomy in DeciduousMolars.<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086550/#>.
- 36.Havale R, Anegundi RT, Indushekar K, Sudha P. Clinical and radiographic evaluation of pulpotomies in primary molars with formocresol, glutaraldehyde and ferric sulphate. *Oral Health Dent Manag* 2013;12:24-31.

37.Fuks AB, Bimstein E, Guelmann M, Klein H. Assessment of a 2 percent buffered glutaraldehyde solution in pulpotomized primary teeth of school children. *ASDC J Dent Child* 1990;57:371-5.

38.Tsai TP, Su HL, Tseng LH. Glutaraldehyde preparations and pulpotomy in primary molars. *Oral Surg Oral Med Oral Pathol* 1993;76:346-50.